Drug intelligence / Profile preview

RJ4960

Development stage: Preclinical
Lead developer: Nanjing Ruijie Pharmaceutical Technology
Modality: Small Molecules

Overview

RJ4960 is a small molecule inhibitor of Spleen Tyrosine Kinase (SYK) currently in early-stage development by Nanjing Ruijie Pharma. SYK is a non-receptor cytoplasmic tyrosine kinase that plays a critical role in signaling from various immune receptors, including B-cell receptors (BCR) and Fc receptors. By inhibiting SYK, RJ4960 aims to modulate immune responses, potentially for the treatment of autoimmune diseases or hematological malignancies, although its specific indications remain undisclosed by the developer.

Targets

SYK (Spleen Tyrosine Kinase)

Beyond the preview

Go deeper on RJ4960.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ4960.

Explore the full profile